Grace Therapeutics, Inc. Current Derivative Financial Liabilities
Grace Therapeutics, Inc. (GRCE) had Current Derivative Financial Liabilities of CAD 16.26 million as of 2019-03-31, per its 20-F filed 2019-06-26.
Discontinued › Notes
ifrs-full:CurrentDerivativeFinancialLiabilities · last filed 2019-06-26
- 2019-03-31: Current Derivative Financial Liabilities 16.26M CAD.
- 2018-03-31: Current Derivative Financial Liabilities 6.43M CAD.
- 2017-03-31: Current Derivative Financial Liabilities 209.00K CAD.
- 2017-02-28: Current Derivative Financial Liabilities 187.00K CAD.
| Period end | Current Derivative Financial Liabilities |
|---|---|
| 2019-03-31 | 16.26M CAD 20-F · filed 2019-06-26 |
| 2018-03-31 | 6.43M CAD 20-F · filed 2019-06-26 |
| 2017-03-31 | 209.00K CAD 20-F · filed 2018-06-29 |
| 2017-02-28 | 187.00K CAD 20-F · filed 2018-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |